Apyx Medical Corporation Financials

APYX

Trailing 12 months to June 30, 2026

Revenue $58.4M +25.6% YoY

Net Income -$8.6M +50.0% YoY

EPS (Diluted) Not reported for the trailing 12 months

Free Cash Flow -$11.0M -10.1% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Apyx Medical Corporation (APYX) reported $58.4M in revenue over the twelve months to Jun 30, 2026, up 25.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI APYX FY2025 2026-08-29

Apyx’s 2025 rebound came from expense compression, while balance-sheet leverage still separates liquidity from operating self-funding.

Cash conversion improved with the earnings recovery: operating cash flow was -$8.0M in FY2025 versus -$18.0M in FY2024, while net loss narrowed to -$11.2M from -$23.5M. However, free cash flow remained -$9.1M, showing that the reduced operating cash deficit still did not fund investment spending.

The 2025 improvement was not mainly a gross-margin story: revenue reached $52.8M while gross margin recovered only to 62.5% from 61.0%. Instead, cost containment drove operating improvement, with selling, general and administrative expense falling to $15.8M and research and development to $3.4M.

A current ratio of 5.0x indicates substantial short-term asset coverage, but debt-to-equity remained elevated at 2.4x as equity stayed near $14.5M. The reported liquidity comparison equaled 47.6 months of the latest annual operating outflow, alongside $9.6M of financing inflow, so liquidity was supported externally rather than generated entirely by operations.

Financial Health Signals

Financial Health Score 43/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Apyx Medical Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

0.94

Apyx Medical Corporation scores 0.94, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($129.7M) relative to total liabilities ($52.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Apyx Medical Corporation passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Apyx Medical Corporation reported a net loss of $11.2M while operations used $8.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Apyx Medical Corporation reported an operating loss of $6.4M against $5.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$52.8M

YoY+9.9%

5Y CAGR+13.8%

10Y CAGR+6.0%

Apyx Medical Corporation generated $52.8M in revenue in fiscal year 2025. This represents an increase of 9.9% from the prior year.

EBITDA

-$5.8M

YoY+68.3%

Apyx Medical Corporation's EBITDA was -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.3% from the prior year.

Net Income

-$11.2M

YoY+52.2%

Apyx Medical Corporation reported -$11.2M in net income in fiscal year 2025. This represents an increase of 52.2% from the prior year.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$9.1M

YoY+51.4%

Apyx Medical Corporation recorded an outflow of $9.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 51.4% from the prior year.

Cash & Debt

$31.7M

YoY0.0%

5Y CAGR-5.4%

10Y CAGR+10.4%

Apyx Medical Corporation held $31.7M in cash against $34.8M in long-term debt as of fiscal year 2025.

Shares Outstanding

42M

YoY+10.7%

5Y CAGR+4.0%

Apyx Medical Corporation had 42M shares outstanding in fiscal year 2025. This represents an increase of 10.7% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

62.5%

YoY+1.5pp

5Y CAGR-0.6pp

10Y CAGR+20.0pp

Apyx Medical Corporation's gross margin was 62.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the prior year.

Operating Margin

-12.2%

YoY+27.0pp

5Y CAGR+60.3pp

10Y CAGR+11.5pp

Apyx Medical Corporation's operating margin was -12.2% in fiscal year 2025, reflecting core business profitability. This is up 27.0 percentage points from the prior year.

Net Margin

-21.2%

YoY+27.6pp

5Y CAGR+21.7pp

10Y CAGR-3.0pp

Apyx Medical Corporation's net profit margin was -21.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 27.6 percentage points from the prior year.

Return on Equity

-77.1%

YoY+88.0pp

5Y CAGR-58.4pp

10Y CAGR-54.2pp

Apyx Medical Corporation's ROE was -77.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 88.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$3.4M

YoY-33.6%

5Y CAGR-3.0%

10Y CAGR+4.6%

Apyx Medical Corporation invested $3.4M in research and development in fiscal year 2025. This represents a decrease of 33.6% from the prior year.

Capital Expenditures

$1.1M

YoY+54.3%

5Y CAGR+13.9%

10Y CAGR+10.2%

Apyx Medical Corporation invested $1.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

APYX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APYX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$58.4M	$52.8M+9.9%	$48.1M-8.1%	$52.3M+17.6%	$44.5M-8.3%	$48.5M+75.1%	$27.7M-1.9%	$28.2M+70.0%	$16.6M+62.3%	$10.2M+16.0%	$8.8M-70.1%	$29.5M+6.6%	$27.7M+17.0%	$23.7M-14.5%	$27.7M+8.9%	$25.4M
Cost of Revenue	$21.3M	$19.8M+5.6%	$18.7M+0.8%	$18.6M+20.9%	$15.4M+3.1%	$14.9M+46.1%	$10.2M+11.7%	$9.1M+58.2%	$5.8M+76.4%	$3.3M-11.5%	$3.7M-78.2%	$17.0M-9.2%	$18.7M+29.2%	$14.5M-11.5%	$16.3M+11.3%	$14.7M
Gross Profit	$37.1M	$33.0M+12.5%	$29.4M-13.0%	$33.8M+15.9%	$29.1M-13.3%	$33.6M+92.0%	$17.5M-8.3%	$19.1M+76.4%	$10.8M+55.6%	$7.0M+36.0%	$5.1M-59.3%	$12.6M+39.6%	$9.0M-2.2%	$9.2M-18.8%	$11.3M+5.6%	$10.7M
R&D Expenses	$3.3M	$3.4M-33.6%	$5.1M-6.6%	$5.4M+19.7%	$4.5M+5.2%	$4.3M+10.2%	$3.9M+5.1%	$3.7M+46.4%	$2.5M+31.3%	$1.9M+87.9%	$1.0M-52.2%	$2.2M+52.5%	$1.4M+12.4%	$1.3M-5.2%	$1.3M+11.0%	$1.2M
SG&A Expenses	$16.9M	$15.8M-16.2%	$18.9M-15.0%	$22.2M+8.4%	$20.5M+10.0%	$18.6M+59.3%	$11.7M-14.7%	$13.7M+45.6%	$9.4M+8.3%	$8.7M+40.5%	$6.2M-26.5%	$8.4M+25.9%	$6.7M+15.7%	$5.8M+33.1%	$4.3M-0.1%	$4.3M
Operating Income	-$3.5M	-$6.4M+65.8%	-$18.8M-9.2%	-$17.3M+26.8%	-$23.6M-63.1%	-$14.4M+28.1%	-$20.1M+3.8%	-$20.9M-46.2%	-$14.3M-2.8%	-$13.9M-21.9%	-$11.4M-63.1%	-$7.0M-19.4%	-$5.8M-59.5%	-$3.7M-450.5%	$1.0M+5911.1%	-$18K
Interest Expense	$5.6M	$5.6M-5.4%	$5.9M+138.4%	$2.5M+16420.0%	$15K+50.0%	$10K-78.3%	$46K+475.0%	$8K-92.3%	$104K-23.5%	$136K-13.9%	$158K+200.0%	-$158K-4.6%	-$151K+36.3%	-$237K-2.2%	-$232K+2.1%	-$237K
Income Tax	$439K	$270K+7.1%	$252K+110.4%	-$2.4M-762.7%	$367K-3.4%	$380K+105.1%	-$7.5M-5671.5%	-$130K+96.7%	-$3.9M-2404.5%	-$156K-343.8%	$64K+156.0%	$25K-99.4%	$4.0M+347.8%	-$1.6M-843.3%	$217K+181.8%	$77K
Net Income	-$8.6M	-$11.2M+52.2%	-$23.5M-25.4%	-$18.7M+19.3%	-$23.2M-52.8%	-$15.2M-27.5%	-$11.9M+39.6%	-$19.7M-131.4%	$62.7M+1339.0%	-$5.1M+56.2%	-$11.6M-115.1%	-$5.4M+68.9%	-$17.3M-298.3%	-$4.3M-803.2%	$617K+466.1%	$109K
EPS (Diluted)	—	N/A	N/A	-$0.54+19.4%	-$0.67-52.3%	-$0.44-25.7%	-$0.35+39.7%	-$0.58-131.7%	$1.83+1176.5%	-$0.17	-$0.15-162.5%	$0.24+123.3%	-$1.03	-$0.40	$0.03	$0.01

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$13.9M+11.2%	$12.5M-34.8%	$19.2M+48.8%	$12.9M+13.2%	$11.4M+20.6%	$9.4M-33.7%	$14.2M+23.8%	$11.5M
Cost of Revenue	$5.0M+9.8%	$4.6M-36.3%	$7.2M+56.4%	$4.6M+6.8%	$4.3M+13.9%	$3.8M-28.4%	$5.3M+16.0%	$4.5M
Gross Profit	$8.9M+11.9%	$7.9M-34.0%	$12.0M+44.6%	$8.3M+17.1%	$7.1M+25.0%	$5.7M-36.8%	$9.0M+28.9%	$7.0M
R&D Expenses	$793K+3.7%	$765K-19.0%	$944K+17.9%	$801K-2.8%	$824K+2.5%	$804K-28.0%	$1.1M-2.2%	$1.1M
SG&A Expenses	$5.3M+47.8%	$3.6M-19.0%	$4.4M+20.8%	$3.7M-14.3%	$4.3M+23.1%	$3.5M-28.3%	$4.8M+12.6%	$4.3M
Operating Income	-$1.8M-98.2%	-$911K-8381.8%	$11K+101.3%	-$832K+67.7%	-$2.6M+15.6%	-$3.1M-0.1%	-$3.0M+16.1%	-$3.6M
Interest Expense	$1.4M+1.8%	$1.4M-2.7%	$1.4M-0.4%	$1.4M+1.4%	$1.4M+1.2%	$1.4M-16.8%	$1.7M+15.5%	$1.4M
Income Tax	$124K-13.3%	$143K+52.1%	$94K+20.5%	$78K+59.2%	$49K0.0%	$49K-44.9%	$89K+48.3%	$60K
Net Income	-$3.2M-53.8%	-$2.1M-62.3%	-$1.3M+34.5%	-$2.0M+47.5%	-$3.8M+9.0%	-$4.2M+10.3%	-$4.6M+1.6%	-$4.7M

Not reported in any period shown, so not listed: EPS (Diluted).

APYX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APYX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$66.8M+3.1%	$64.8M-18.2%	$79.2M+53.0%	$51.8M-24.7%	$68.7M-7.3%	$74.1M-12.5%	$84.7M-11.7%	$95.9M+209.6%	$31.0M-11.7%	$35.1M+11.6%	$31.4M+26.6%	$24.8M-25.1%	$33.2M+17.7%	$28.2M-0.2%	$28.2M
Current Assets	$58.5M+3.6%	$56.4M-19.8%	$70.4M+63.7%	$43.0M-29.2%	$60.7M-8.1%	$66.1M-13.9%	$76.7M-14.6%	$89.8M+298.4%	$22.5M-15.0%	$26.5M+20.4%	$22.0M+43.5%	$15.4M-22.5%	$19.8M+22.0%	$16.2M-1.5%	$16.5M
Cash & Equivalents	$31.7M0.0%	$31.7M-27.3%	$43.7M+328.3%	$10.2M-67.0%	$30.9M-26.4%	$41.9M-28.7%	$58.8M+254.4%	$16.6M+66.8%	$9.9M-31.2%	$14.5M+22.5%	$11.8M+105.9%	$5.7M-27.7%	$7.9M+90.4%	$4.2M-14.7%	$4.9M
Inventory	$8.6M+13.7%	$7.6M-23.8%	$9.9M-15.9%	$11.8M+74.0%	$6.8M+67.3%	$4.1M-20.1%	$5.1M-4.3%	$5.3M+23.9%	$4.3M-30.6%	$6.2M+3.4%	$6.0M+4.0%	$5.7M-31.9%	$8.4M+11.6%	$7.5M-7.8%	$8.2M
Accounts Receivable	$16.8M+8.4%	$15.5M+10.4%	$14.0M+32.3%	$10.6M-18.7%	$13.0M+55.2%	$8.4M+5.2%	$8.0M+57.2%	$5.1M+4.6%	$4.9M+2.6%	$4.7M+61.8%	$2.9M+46.8%	$2.0M+0.1%	$2.0M-30.8%	$2.9M+29.7%	$2.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$185K0.0%	$185K0.0%	$185K0.0%	$185K	N/A	N/A	N/A	N/A
Total Liabilities	$52.0M+3.0%	$50.5M-3.5%	$52.3M+274.2%	$14.0M-5.0%	$14.7M+43.5%	$10.3M-24.0%	$13.5M+54.1%	$8.8M-2.3%	$9.0M+0.8%	$8.9M+10.5%	$8.0M-60.1%	$20.1M+70.0%	$11.8M+124.0%	$5.3M-13.6%	$6.1M
Current Liabilities	$11.7M+9.1%	$10.7M-15.8%	$12.7M+7.5%	$11.8M-10.3%	$13.2M+44.3%	$9.2M-25.7%	$12.3M+43.0%	$8.6M+44.2%	$6.0M+13.3%	$5.3M+27.9%	$4.1M+9.4%	$3.8M+29.3%	$2.9M+51.5%	$1.9M-19.5%	$2.4M
Long-Term Debt	$34.8M+2.8%	$33.9M+2.1%	$33.2M	$0	N/A	N/A	N/A	$0-100.0%	$2.5M-8.9%	$2.7M-8.2%	$2.9M	N/A	$3.2M	N/A	N/A
Total Equity	$14.5M+2.3%	$14.2M-46.8%	$26.7M-29.0%	$37.6M-30.0%	$53.7M-15.7%	$63.7M-10.6%	$71.3M-18.3%	$87.2M+295.7%	$22.0M-16.0%	$26.2M+12.0%	$23.4M+1456.1%	$1.5M-92.1%	$19.1M-16.7%	$22.9M+3.5%	$22.1M
Retained Earnings	-$89.1M-14.4%	-$77.9M-43.1%	-$54.4M-52.4%	-$35.7M-184.7%	-$12.6M-578.9%	$2.6M-81.9%	$14.5M-57.6%	$34.2M+220.1%	-$28.5M-21.6%	-$23.4M-20.3%	-$19.5M+30.0%	-$27.8M-189.1%	-$9.6M-264.9%	-$2.6M+18.9%	-$3.3M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$61.1M-3.1%	$63.0M-5.7%	$66.8M+16.5%	$57.4M-1.4%	$58.2M-3.3%	$60.2M-7.2%	$64.8M+6.8%	$60.7M
Current Assets	$53.2M-3.0%	$54.8M-6.3%	$58.5M+19.8%	$48.8M-2.3%	$49.9M-3.7%	$51.9M-8.1%	$56.4M+8.2%	$52.2M
Cash & Equivalents	$27.6M-11.3%	$31.1M-1.9%	$31.7M+26.3%	$25.1M-14.2%	$29.3M-5.5%	$31.0M-2.3%	$31.7M+13.3%	$28.0M
Inventory	$10.7M+12.7%	$9.5M+10.9%	$8.6M-5.9%	$9.1M+11.6%	$8.2M+6.6%	$7.7M+1.6%	$7.6M-16.0%	$9.0M
Accounts Receivable	$13.6M+6.7%	$12.8M-24.0%	$16.8M+29.1%	$13.0M+15.5%	$11.2M-3.4%	$11.6M-24.8%	$15.5M+18.7%	$13.0M
Total Liabilities	$50.0M+0.1%	$49.9M-4.0%	$52.0M+1.4%	$51.3M+1.1%	$50.7M+2.5%	$49.5M-2.0%	$50.5M+2.0%	$49.5M
Current Liabilities	$9.4M-1.0%	$9.4M-19.3%	$11.7M+6.6%	$11.0M+3.9%	$10.6M+11.1%	$9.5M-11.3%	$10.7M+12.2%	$9.6M
Long-Term Debt	$35.3M+0.7%	$35.1M+0.7%	$34.8M+0.7%	$34.6M+0.7%	$34.4M+0.7%	$34.1M+0.7%	$33.9M+0.1%	$33.9M
Total Equity	$10.7M-16.9%	$12.8M-11.7%	$14.5M+148.6%	$5.8M-19.4%	$7.3M-31.0%	$10.5M-26.0%	$14.2M+28.7%	$11.0M
Retained Earnings	-$94.5M-3.6%	-$91.2M-2.4%	-$89.1M-1.5%	-$87.8M-2.3%	-$85.8M-4.6%	-$82.1M-5.3%	-$77.9M-6.3%	-$73.3M

Not reported in any period shown, so not listed: Goodwill.

APYX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

APYX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$10.1M	-$8.0M+55.7%	-$18.0M-243.8%	-$5.2M+74.1%	-$20.3M-94.1%	-$10.4M+35.0%	-$16.1M+13.0%	-$18.5M+11.5%	-$20.9M-463.7%	-$3.7M-30.6%	-$2.8M+51.0%	-$5.8M-1287.5%	-$417K+83.6%	-$2.5M-1637.0%	$165K-91.3%	$1.9M
Capital Expenditures	$920K	$1.1M+54.3%	$722K+35.5%	$533K-47.2%	$1.0M+39.7%	$723K+24.4%	$581K-55.3%	$1.3M+258.4%	$363K-41.8%	$624K+118.2%	$286K-32.1%	$421K-33.2%	$630K+7.1%	$588K-21.9%	$753K+38.9%	$542K
Free Cash Flow	-$11.0M	-$9.1M+51.4%	-$18.8M-224.6%	-$5.8M+72.8%	-$21.3M-90.6%	-$11.2M+32.9%	-$16.6M+15.8%	-$19.8M+6.9%	-$21.2M-390.9%	-$4.3M-38.6%	-$3.1M+49.7%	-$6.2M-492.8%	-$1.0M+66.5%	-$3.1M-431.3%	-$588K-143.4%	$1.4M
Investing Cash Flow	-$920K	-$1.1M-54.3%	-$722K-110.7%	$6.7M+766.7%	-$1.0M-39.7%	-$723K-24.4%	-$581K-101.0%	$60.5M+106.6%	$29.3M+4795.7%	-$624K-118.2%	-$286K+68.9%	-$921K-46.2%	-$630K-7.1%	-$588K+21.9%	-$753K-38.9%	-$542K
Financing Cash Flow	$9.6M	$9.6M+42.0%	$6.7M-79.0%	$32.2M+14723.0%	$217K+804.2%	$24K+132.9%	-$73K-149.7%	$147K+105.9%	-$2.5M-942.7%	-$239K-104.2%	$5.7M-55.3%	$12.8M+1217.0%	-$1.1M-116.6%	$6.9M+5396.9%	-$130K+57.0%	-$302K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$3.5M-510.1%	-$572K+77.4%	-$2.5M+28.5%	-$3.5M-186.8%	-$1.2M-75.6%	-$702K+76.1%	-$2.9M+33.9%	-$4.4M
Capital Expenditures	$66K+10.0%	$60K-78.2%	$275K-47.0%	$519K+95.8%	$265K+381.8%	$55K-77.6%	$245K+60.1%	$153K
Free Cash Flow	-$3.6M-462.7%	-$632K+77.5%	-$2.8M+30.8%	-$4.1M-170.7%	-$1.5M-97.9%	-$757K+76.2%	-$3.2M+30.7%	-$4.6M
Investing Cash Flow	-$66K-10.0%	-$60K+78.2%	-$275K+47.0%	-$519K-95.8%	-$265K-381.8%	-$55K+77.6%	-$245K-60.1%	-$153K
Financing Cash Flow	-$5K-106.0%	$83K-99.1%	$9.5M+20977.8%	$45K+80.0%	$25K0.0%	$25K-99.6%	$6.8M+135300.0%	-$5K

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

APYX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

APYX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	62.5%+1.5pp	61.0%-3.4pp	64.5%-1.0pp	65.5%-3.8pp	69.3%+6.1pp	63.2%-4.5pp	67.6%+2.4pp	65.2%-2.8pp	68.0%+10.0pp	58.0%+15.5pp	42.5%+10.1pp	32.5%-6.4pp	38.9%-2.1pp	41.0%-1.3pp	42.2%
Operating Margin	-12.2%+27.0pp	-39.2%-6.2pp	-33.0%+20.0pp	-52.9%-23.2pp	-29.8%+42.7pp	-72.5%+1.4pp	-73.9%+12.1pp	-86.0%	-135.7%	-129.2%	-23.7%-2.5pp	-21.1%-5.6pp	-15.5%-19.3pp	3.8%+3.9pp	-0.1%
Net Margin	-21.2%+27.6pp	-48.8%-13.0pp	-35.8%+16.3pp	-52.1%-20.8pp	-31.3%+11.7pp	-42.9%+26.9pp	-69.8%	377.7%	-49.5%	-131.0%	-18.2%+44.2pp	-62.4%-44.1pp	-18.3%-20.6pp	2.2%+1.8pp	0.4%
Return on Equity	-77.1%+88.0pp	-165.1%-95.0pp	-70.1%-8.4pp	-61.7%-33.4pp	-28.2%-9.6pp	-18.7%+9.0pp	-27.7%-99.6pp	71.9%+94.9pp	-23.0%+21.1pp	-44.0%-21.1pp	-22.9%+1126.1pp	-1149.1%-1126.3pp	-22.8%-25.4pp	2.7%+2.2pp	0.5%
Return on Assets	-16.8%+19.4pp	-36.2%-12.6pp	-23.6%+21.2pp	-44.8%-22.7pp	-22.1%-6.0pp	-16.1%+7.2pp	-23.3%-88.6pp	65.4%+81.7pp	-16.3%+16.6pp	-32.9%-15.8pp	-17.1%+52.5pp	-69.6%-56.5pp	-13.1%-15.3pp	2.2%+1.8pp	0.4%
Current Ratio	5.00-0.3x	5.26-0.3x	5.52+1.9x	3.63-1.0x	4.60-2.6x	7.22+1.0x	6.23-4.2x	10.43+6.7x	3.77-1.3x	5.03-0.3x	5.35+1.3x	4.08-2.7x	6.81-1.6x	8.45+1.6x	6.90
Debt-to-Equity	2.400.0x	2.39+1.1x	1.24+1.2x	0.00-0.3x	0.27+0.1x	0.160.0x	0.19+0.2x	0.00-0.1x	0.110.0x	0.100.0x	0.13-13.3x	13.39+13.2x	0.17-0.1x	0.230.0x	0.28
FCF Margin	-17.3%+21.8pp	-39.0%-28.0pp	-11.1%+36.8pp	-47.8%-24.8pp	-23.0%+37.0pp	-60.1%+10.0pp	-70.0%	-127.9%	-42.3%-6.9pp	-35.4%-14.4pp	-21.0%-17.3pp	-3.8%+9.4pp	-13.2%-11.1pp	-2.1%-7.4pp	5.3%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	63.9%+0.4pp	63.4%+0.8pp	62.6%-1.8pp	64.4%+2.1pp	62.3%+2.2pp	60.1%-3.0pp	63.0%+2.5pp	60.5%
Operating Margin	-13.0%-5.7pp	-7.3%-7.4pp	0.1%+6.5pp	-6.5%+16.2pp	-22.6%+9.7pp	-32.4%-10.9pp	-21.4%+10.2pp	-31.6%
Net Margin	-23.4%-6.5pp	-16.9%-10.1pp	-6.8%+8.6pp	-15.4%+17.8pp	-33.2%+10.8pp	-44.0%-11.5pp	-32.5%+8.4pp	-40.9%
Return on Equity	-30.4%-14.0pp	-16.4%-7.5pp	-8.9%+25.0pp	-33.9%+18.2pp	-52.1%-12.6pp	-39.5%-6.9pp	-32.6%+10.0pp	-42.6%
Return on Assets	-5.3%-2.0pp	-3.3%-1.4pp	-1.9%+1.5pp	-3.5%+3.0pp	-6.5%+0.4pp	-6.9%+0.2pp	-7.1%+0.6pp	-7.8%
Current Ratio	5.68-0.1x	5.80+0.8x	5.00+0.6x	4.44-0.3x	4.72-0.7x	5.45+0.2x	5.26-0.2x	5.46
Debt-to-Equity	3.31+0.6x	2.73+0.3x	2.40-3.5x	5.92+1.2x	4.74+1.5x	3.25+0.9x	2.39-0.7x	3.07
FCF Margin	-25.6%-20.5pp	-5.1%+9.6pp	-14.6%+16.9pp	-31.5%-18.3pp	-13.2%-5.1pp	-8.0%+14.3pp	-22.4%+17.6pp	-40.0%

Similar Companies

Xtant Medical XTNT

$53.9M

Pulmonx Corp LUNG

$102.2M

Baird Medical BDMD

$35.8M

IceCure Medical Ltd. ICCM

$7.9M

Tela Bio, Inc. TELA

$31.4M

Where Apyx Medical Corporation Ranks

Frequently Asked Questions

What is Apyx Medical Corporation's annual revenue?

Apyx Medical Corporation (APYX) reported $52.8M in total revenue for fiscal year 2025. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Apyx Medical Corporation's revenue growing?

Apyx Medical Corporation (APYX) revenue grew by 9.9% year-over-year, from $48.1M to $52.8M in fiscal year 2025.

Is Apyx Medical Corporation profitable?

No, Apyx Medical Corporation (APYX) reported a net income of -$11.2M in fiscal year 2025, with a net profit margin of -21.2%.

What is Apyx Medical Corporation's EBITDA?

Apyx Medical Corporation (APYX) had EBITDA of -$5.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Apyx Medical Corporation have?

As of fiscal year 2025, Apyx Medical Corporation (APYX) had $31.7M in cash and equivalents against $34.8M in long-term debt.

What is Apyx Medical Corporation's gross margin?

Apyx Medical Corporation (APYX) had a gross margin of 62.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Apyx Medical Corporation's operating margin?

Apyx Medical Corporation (APYX) had an operating margin of -12.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Apyx Medical Corporation's net profit margin?

Apyx Medical Corporation (APYX) had a net profit margin of -21.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Apyx Medical Corporation's return on equity (ROE)?

Apyx Medical Corporation (APYX) has a return on equity of -77.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Apyx Medical Corporation's free cash flow?

Apyx Medical Corporation (APYX) recorded an outflow of $9.1M in free cash flow during fiscal year 2025. This represents a 51.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Apyx Medical Corporation's operating cash flow?

Apyx Medical Corporation (APYX) recorded an outflow of $8.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Apyx Medical Corporation's total assets?

Apyx Medical Corporation (APYX) had $66.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Apyx Medical Corporation's capital expenditures?

Apyx Medical Corporation (APYX) invested $1.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Apyx Medical Corporation spend on research and development?

Apyx Medical Corporation (APYX) invested $3.4M in research and development during fiscal year 2025.

How many shares does Apyx Medical Corporation have outstanding?

Apyx Medical Corporation (APYX) had 42M shares outstanding as of fiscal year 2025.

What is Apyx Medical Corporation's current ratio?

Apyx Medical Corporation (APYX) had a current ratio of 5.00 as of fiscal year 2025, which is generally considered healthy.

What is Apyx Medical Corporation's debt-to-equity ratio?

Apyx Medical Corporation (APYX) had a debt-to-equity ratio of 2.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Apyx Medical Corporation's return on assets (ROA)?

Apyx Medical Corporation (APYX) had a return on assets of -16.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Apyx Medical Corporation's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Apyx Medical Corporation (APYX) held $31.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.0M over that year. Dividing the one by the other, the reported balance equals about 48 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Apyx Medical Corporation's Altman Z-Score?

Apyx Medical Corporation (APYX) has an Altman Z-Score of 0.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Apyx Medical Corporation's Piotroski F-Score?

Apyx Medical Corporation (APYX) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Apyx Medical Corporation's earnings high quality?

Apyx Medical Corporation (APYX) reported a net loss of $11.2M while operations used $8.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Apyx Medical Corporation cover its interest payments?

Apyx Medical Corporation (APYX) reported an operating loss of $6.4M against $5.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Apyx Medical Corporation?

Apyx Medical Corporation (APYX) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.